The featured speaker will detail how our immune system responds to infection, how variants such as Omicron emerge and the featured speaker will also delineate the different outcomes that can result, including long COVID.

TORONTO (PRWEB)
January 19, 2022

This webinar will focus on the origin and biology of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. More specifically, the featured speaker will detail how our immune system responds to infection, how variants such as Omicron emerge and the featured speaker will also delineate the different outcomes that can result, including long COVID. The webinar will also be open to questions should you wish to discuss any other topics of interest relating to this virus.

Register for the webinar to learn everything that is presently known about this virus and the diseases it causes.

Join Benjamin tenOever, PhD, Professor of Microbiology and the Director of the Virus Research Institute, New York University, for the live webinar on Wednesday, February 9, 2022 at 2pm EST.

For more information, or to register for this event, visit Biology of SARS-CoV-2: Past, Present and Future.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Dr. Steve W. Ross, OceanGate Expeditions Titanic Survey Expedition Chief Scientist

We are seeking to compile a list of every living creature we can identify inhabiting the Titanic wreck site to understand this unique deep-sea ecosystem. This has never been attempted before. Dr. Steve W. Ross

NASSAU, Bahamas (PRWEB)
January 18, 2022

OceanGate Expeditions announces that Dr. Steve W. Ross, Research Professor at the University of North Carolina at Wilmington, will be the Chief Scientist of the 2022 Titanic Survey Expedition. Dr. Ross will lead a team of accomplished scientists in a first-of-its-kind survey of the marine ecosystems on and near the Titanic. The wreck of the Titanic, sitting at 3,800 meters on a barren abyssal plain, serves as a refuge for life forms like corals, squat lobsters, brittle stars, and rattail fish. The scientific team will utilize the 5-crewmember Titan submersible as a research platform to observe and record the deep dwelling sea life.

“Previous dives to the Titanic have focused mostly on the wreck and associated archaeology. We are seeking to compile a list of every living creature we can identify inhabiting the Titanic wreck site to understand this unique deep-sea ecosystem. This has never been attempted before,” says marine biology expert Dr. Steve W. Ross. “Unlike ROVs (remotely operated vehicles), using direct observation from the Titan submersible provides a better depth of field and a fuller impression of what the surrounding environment is like. We want to understand what sustains the fish and corals that make this deep ocean artificial reef their home, what is in the water column, and add a biological layer to the GIS mapping effort that began during last year’s expedition. In addition to collecting important ecological and archaeological data, we hope this new information will also contribute to conservation of the wreck site,” continues Dr. Ross.

“It was fascinating to observe numerous creatures during our dives to the Titanic in 2021. We are privileged to have Dr. Ross shepherding this unprecedented project that promises to shed light on this remarkable underwater community,” says Stockton Rush, President, OceanGate Expeditions. “Dr. Ross brings some 45 years of deep ocean research experience to the 2022 Titanic Expedition. Dr. Ross has authored many frequently cited studies of deep sea corals and fish populations in submarine canyons and other locations, and he will be integral to uncovering the mysteries of this unique undersea habitat,” explains Rush.

The scientific team headed by Dr. Ross will be supported by OceanGate Expeditions crewmembers and citizen explorers who will serve as Mission Specialists for this important marine ecological study. In addition to U.S. biologists and archaeologists, the research team will include renowned colleagues from Canada and the UK. Aspiring Mission Specialists interested in supporting the Titanic Survey Expedition should contact OceanGate Expeditions for qualifications, availability, and additional details.

###

Media Inquiries | Lisa Dreher | lisa.dreher@oceangateexpeditions.com | +1 425-442-1301

Expedition Inquiries | Kyle Bingham | kyle.bingham@oceangateexpeditions.com | +1 425-595-6343

Investor Inquiries | Bob Shuman | robert.shuman@oceangatexpeditions.com | +1 425-595-5017

Business Inquiries | Bob Shuman | robert.shuman@oceangatexpeditions.com | +1 425-595-5017

CLICK HERE TO DOWNLOAD IMAGES

ABOUT OCEANGATE EXPEDITIONS

OceanGate Expeditions, Ltd is dedicated to direct human exploration of the undersea world. Not satisfied with scratching the surface of the ocean near the shoreline, OceanGate Expeditions charters manned submersibles to create expeditions at depths far deeper than can be reached with SCUBA. The organization conducts undersea expeditions to explore and document the 95% of the seafloor that man has never visited including iconic shipwrecks, hydrothermal vents, deep-sea canyons, and uncommon biological events around the world. These expeditions, to depths approaching 4,000 meters (13,123 feet), provide rare opportunities for citizen scientists to observe the mysteries of the deep sea and expand our understanding of our home, Earth, the blue planet. Visit http://www.oceangateexpeditions.com.

Follow OceanGate Expeditions on: YouTube | Instagram | Facebook | Twitter | LinkedIn

Share article on social media or email:

INDIGO Biosciences Logo

“We are excited to offer INDIGlo, our new firefly luciferase detection reagent, to our customers,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “It is an ideal, detection reagent for both low- and high-throughput batch processing of compounds.”

STATE COLLEGE, Pa. (PRWEB)
January 18, 2022

INDIGO Biosciences, Inc. (INDIGO), a recognized industry leader in cell-based luciferase reporter assay kits and service, has developed a new luciferase detection reagent and will be offering this new reagent solely for purchase. INDIGlo, the companies new Luciferase Detection Reagent Kit will provide researchers with the ability to purchase the easy-to-use reagent found in INDIGO products for their own use to investigate a variety of cellular processes.

“We are excited to offer INDIGlo, our new firefly luciferase detection reagent, to our customers,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “It is an ideal, detection reagent for both low- and high-throughput batch processing of compounds.”

Luciferase assays are utilized for research in drug development, environmental monitoring, toxicology, as well as many other types of research. Researchers use luciferase assays bioluminescent light output as a sensitive measure of biological activity. Luciferase assays are specifically used for cell-based target validation, pathway analysis, investigating protein function, researching miRNA regulation, and performing compound screenings.

Luciferase assays are preferred by researchers due to their increased sensitivity and precision compared to their fluorescent counterparts. This is because unlike with fluorescence, there is no inherent background luminescence in mammalian cells, which allows a luciferase assay to be extremely sensitive with a greater dynamic linear-response range. Bioluminescence assays also very rarely encounter test compounds with inherent light emission properties. So besides not having to deal with a high signal-to-noise ratio, luciferase-based assays do not have to contend with false signals coming from test compounds themselves.

Luciferase detection reagents are what provide a substrate to convert the activity of the luciferase enzyme into a light signal. It is what lets firefly luciferase reporter assays like those developed by INDIGO to work.

The INDIGlo Luciferase Detection Reagent from INDIGO Biosciences is a glow type luciferase detection reagent with a signal duration of greater than 2 hour with a less than 10% fluctuation in signal. The reagent is provided ‘ready to use’ and is formulated as a 2x-concentrated reagent, thereby allowing greater versatility in its use. The highly sensitive and stable luminescence signal of INDIGlo is ideal for the cost-effective processing of cell culture plates ranging from 96 to 1536-well format. INDIGlo is available for purchase in a variety of formats through INDIGO as well as INDIGO’s distribution partners.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at https://indigobiosciences.com/.

Share article on social media or email:

Catalent’s Philadelphia Facility

Advanced therapeutics require increasingly complex handling requirements, and the investment we have made in Philadelphia allows Catalent to operate efficient packaging processes and operations, bridging the gap between clinical scale and niche commercial volumes.

SOMERSET, N.J. (PRWEB)
January 11, 2022

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

Work has been undertaken at the facility to expand the packaging area by around 20,000 square feet and includes the addition of seven new temperature-controlled processing suites, which can operate at either refrigerated or frozen conditions to precisely match the needs of the drugs being handled. Further ambient space has also been added for packaging operations and materials storage.

The new suites include full serialization capabilities, specifically designed for small-scale batches of commercial products. Validation of the equipment is expected to be completed by the end of Q1 2022.

“Advanced therapeutics require increasingly complex handling requirements, and the investment we have made in Philadelphia allows Catalent to operate efficient packaging processes and operations, bridging the gap between clinical scale and niche commercial volumes,” commented Ann McMahon, General Manager of Commercial & Integrated Development Operations at Catalent Clinical Supply Services. “The specifically designed packaging areas not only provide optimal commercial opportunities for drug developers, but also the safest working conditions for employees in terms of air exchange rates, carbon dioxide monitoring, and ultraviolet air sanitization.”

The 200,000 square-foot Philadelphia facility is the largest site in Catalent’s global clinical supply network and the company’s North American Center of Excellence for clinical supply packaging. It includes an on-site pharmacy to support FlexDirect® direct-to-patient services for clinical trials, as well as access to Catalent’s FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, and clinical returns and destruction services.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually.

Catalent’s expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

In contrast, the trial found that the vaccine causes severe (grade 3) and grade 4 systemic reactions in children.

NEWPORT BEACH, Calif. (PRWEB)
December 22, 2021

Physicians for Informed Consent (PIC), an educational nonprofit organization focused on science and statistics, has published an update of its Pfizer COVID-19 Vaccine Risk Statement (VRS), which includes important questions and answers about the vaccine. The Pfizer COVID-19 vaccine received expanded emergency use authorization (EUA) for children 5 to 11 years of age; however, the vaccine has not been approved or licensed for children 15 years or younger.

The Pfizer COVID-19 VRS highlights essential data (referenced here) from the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Pfizer clinical trial to help patients and caregivers engage in informed decision-making. Some key points include the following:

• 
  The clinical trial found there were zero cases of severe COVID-19 in children of any age who did not receive the vaccine. In contrast, the trial found that the vaccine causes severe (grade 3) and grade 4 systemic reactions in children.
• 
  The clinical trial indicates that vaccine efficacy declines significantly in less than six months. Although a booster dose of the vaccine is authorized for individuals 16 years of age or older, the clinical trial states that efficacy was not evaluated for Phase 3 BNT162b2 booster group participants. Instead, vaccine efficacy was inferred based on antibody levels observed in only about 300 vaccinated subjects over a one-month time period.
• The clinical trial provided no evidence that the vaccine prevents asymptomatic infection or transmission of SARS-CoV-2 or COVID-19. In addition, recent studies have observed that a significant proportion of severe, critical, and fatal cases of COVID-19 occurred in vaccinated individuals.

“PIC was founded in 2015 to safeguard informed consent in vaccination,” said Dr. Shira Miller, PIC founder and president. “Today, more people than ever before are interested in analyzing infectious disease data and researching vaccines. We are pleased to provide a concise, reader-friendly document that emphasizes important statistics that further assist the public to engage in informed decision-making.”

Earlier this year, PIC introduced its “Do your research” education initiative for COVID-19 vaccines, providing scientific information that reflects the necessity for choice — rather than coercion — in vaccine administration. The newly released VRS helps expand public knowledge. Used together with PIC’s COVID-19 Disease Information Statement (DIS), which discusses effects of COVID-19 in different age groups, the document serves to further aid readers in comparing the risk of COVID-19 infection versus the risk of a severe side effect from a COVID-19 vaccine.

To download your copy of the VRS “Pfizer COVID-19 Vaccine: Short-Term Efficacy & Safety Data,” visit physiciansforinformedconsent.org/COVID-19-vaccines.

About Physicians for Informed Consent

Physicians for Informed Consent is a 501(c)(3) educational nonprofit organization focused on science and statistics. PIC delivers data on infectious diseases and vaccines, and unites doctors, scientists, healthcare professionals, attorneys, and families who support voluntary vaccination. In addition, the PIC Coalition for Informed Consent consists of more than 300 U.S. and international organizations. To learn more or to become a member, please visit physiciansforinformedconsent.org.

Share article on social media or email:

Executive V.P. Jeff Tuel and Pres. Aric Olson, Jain Irrigation

“The New Product Contest award is a great validation by the Irrigation Association and the members of our industry of the importance JAIN Water Management Consulting Services is having,” said Aric Olson, President of Jain Irrigation

FRESNO, Calif. (PRWEB)
December 16, 2021

Jain Irrigation, Inc., the world leader in irrigation technology, today announced that its Water Management Services, where JAIN consultants deliver weekly irrigation schedules to growers based on satellite imagery, hyperlocal weather, and machine learning analysis of soil moisture content and water infiltration properties, has won the Irrigation Association 2021 New Product Contest Award in the Specialty Agriculture Irrigation category. This year’s contest was a hybrid event combining virtual and live elements. Products were evaluated based on innovation, design quality, increased water/resource-use efficiency, ease of use, and product life expectancy. Contest judges are experienced professionals with technical knowledge and industry expertise. Official judging was conducted via Zoom Nov. 17-18, with winners announced live on the Irrigation Show floor on December 9.

Winning in the Specialty Agriculture Irrigation category, JAIN Water Management Services was honored for its highly integrated offering of agtech software, hardware, and consulting services that generate intelligent irrigation schedules; featuring the first-of-its-kind utilization of high-resolution satellite imaging for ETc (crop water consumption), real-time local weather and soil moisture sensing in the field, bundled together with Machine Learning toward providing unprecedented precision in management of when and how long each crop irrigation event needs to last.

Accepting the award, Jeff Tuel, Executive Vice President of Jain Irrigation and head of Water Management Services, said, “Growers today are facing environmental challenges the likes we’ve never seen before, in addition to incredible labor shortages. We developed JAIN Water Management Services to remove the hesitancy in deploying new technologies that can meet these problems head-on. While the tools may be complex, the process is quite simple and relies on tried-and-true soil, plant, and water relationships. The growers get this, and it’s remarkable to see how quickly over the course of the program they’re able to pick up the technology and start producing their own irrigation schedules.”

“The New Product Contest award is a great validation by the Irrigation Association and the members of our industry of the importance JAIN Water Management Services is having,” said Aric Olson, President of Jain Irrigation, “Modern technology makes it easier to manage water than any time before in history, but agtech companies need to meet an even higher bar before farmers are willing to change how they operate and we have to be able to adapt along with them, too. Our ability to train and support customers to become power users of JAIN Logic software, to understand their problems, provides a low cost, low-risk trial of the leading technology available today.”

A short video with stories from three California Central Valley Growers talking about their participation in the inaugural launch of JAIN Water Management Services and how working directly with a JAIN water management consultant helped them successfully adopt and use agtech within a single growing season is now available on the Jain Irrigation YouTube channel at https://youtu.be/fg5C8EJGoY0.

Contact us here to have a consultant call you today. https://jainsusa.com/monitoring-control/water-management-services/

ABOUT JAIN IRRIGATION

JAIN is a fully integrated global food/plant production company recognized by Harvard Business as one of five global sustainability champions and the G-20 to lift people out of poverty. Our irrigation manufacturing capabilities include everything from behind the pump to the flush valve at the end of the lateral and everything in between, including drip irrigation. We lead the industry in manufacturing technology, owning both our extrusion and mold manufacturing equipment providers. Jain leads plant science research globally across various food crops and is staffed with some of the world’s leading research scientists. With the Gandhi Library, Jain now houses the prominent collection of the world’s best plant science knowledge in a single facility. Our agronomic knowledge is integrated from our world-class tissue culture operations through our food processing businesses. We research, educate, advance, manufacture, finance, propagate plants, and purchase produce for processing, all to fulfill the Jain mission, “leave this world better than you found it.”

Share article on social media or email: